Kiromic BioPharma, Inc. (KRBP)
USD 0.08
(-2.33%)
USD 0.08
(-2.33%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -2.79 Million USD | -35.22% |
| 2022 | -2.06 Million USD | -340.1% |
| 2021 | -469.8 Thousand USD | -134.9% |
| 2020 | -200 Thousand USD | -128.57% |
| 2019 | -87.5 Thousand USD | -8.16% |
| 2018 | -80.9 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -557 Thousand USD | 50.73% |
| 2024 Q2 | -557 Thousand USD | 0.0% |
| 2023 Q3 | -560.1 Thousand USD | 19.41% |
| 2023 Q4 | -1.13 Million USD | -101.82% |
| 2023 FY | -2.79 Million USD | -35.22% |
| 2023 Q1 | -555.8 Thousand USD | 41.44% |
| 2023 Q2 | -695 Thousand USD | -25.04% |
| 2022 Q3 | - USD | 100.0% |
| 2022 Q2 | -399.1 Thousand USD | -118.33% |
| 2022 FY | -2.06 Million USD | -340.1% |
| 2022 Q1 | -182.8 Thousand USD | -34.02% |
| 2022 Q4 | -949.1 Thousand USD | 0.0% |
| 2021 Q2 | - USD | 0.0% |
| 2021 FY | -469.8 Thousand USD | -134.9% |
| 2021 Q3 | -131 Thousand USD | 0.0% |
| 2021 Q4 | -136.4 Thousand USD | -4.12% |
| 2021 Q1 | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 FY | -200 Thousand USD | -128.57% |
| 2020 Q1 | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 FY | -87.5 Thousand USD | -8.16% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2018 FY | -80.9 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| America Great Health | 168.58 Thousand USD | 1758.422% |
| Ampio Pharmaceuticals, Inc. | -250 Thousand USD | -1018.36% |
| Aridis Pharmaceuticals, Inc. | - USD | Infinity% |
| Biora Therapeutics, Inc. | -551 Thousand USD | -407.423% |
| Bio-Path Holdings, Inc. | -178 Thousand USD | -1470.73% |
| Better Therapeutics, Inc. | -2.72 Million USD | -2.451% |
| Calithera Biosciences, Inc. | -1.38 Million USD | -101.87% |
| Comera Life Sciences Holdings, Inc. | 422.71 Thousand USD | 761.42% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -22.91 Million USD | 87.801% |
| Eloxx Pharmaceuticals, Inc. | - USD | Infinity% |
| Evelo Biosciences, Inc. | - USD | Infinity% |
| Evolutionary Genomics, Inc. | -1.02 Million USD | -173.707% |
| Finch Therapeutics Group, Inc. | -7.09 Million USD | 60.577% |
| Galera Therapeutics, Inc. | -259 Thousand USD | -979.498% |
| Innovation1 Biotech Inc. | -52.69 Thousand USD | -5205.514% |
| Molecular Templates, Inc. | 50.39 Million USD | 105.548% |
| Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | -2243.686% |
| NexImmune, Inc. | -1.02 Million USD | -172.778% |
| Orgenesis Inc. | -5.72 Million USD | 51.163% |
| Panbela Therapeutics, Inc. | -25.64 Million USD | 89.099% |
| Point of Care Nano-Technology, Inc. | -4601.00 USD | -60667.225% |
| PaxMedica, Inc. Common Stock | - USD | Infinity% |
| Scopus BioPharma Inc. | - USD | Infinity% |
| Sorrento Therapeutics, Inc. | 29.38 Million USD | 109.514% |
| Statera Biopharma, Inc. | -488.31 Thousand USD | -472.562% |
| TRACON Pharmaceuticals, Inc. | -232 Thousand USD | -1105.129% |
| Trevena, Inc. | 1.45 Million USD | 292.158% |
| Vaxxinity, Inc. | -2.23 Million USD | -25.152% |
| Vaccinex, Inc. | -16 Million USD | 82.53% |
| Vicapsys Life Sciences, Inc. | - USD | Infinity% |
| Viracta Therapeutics, Inc. | -492 Thousand USD | -468.272% |
| ZIVO Bioscience, Inc. | 11.61 Thousand USD | 24181.826% |